UK markets closed
  • FTSE 100

    -94.15 (-1.26%)
  • FTSE 250

    -236.13 (-1.26%)
  • AIM

    -7.02 (-0.87%)

    +0.0026 (+0.22%)

    -0.0057 (-0.46%)
  • Bitcoin GBP

    -433.66 (-1.90%)
  • CMC Crypto 200

    -21.06 (-3.41%)
  • S&P 500

    +22.27 (+0.56%)
  • DOW

    +132.28 (+0.41%)

    -0.76 (-1.09%)

    -14.90 (-0.75%)
  • NIKKEI 225

    -34.36 (-0.13%)

    -133.96 (-0.67%)
  • DAX

    -253.16 (-1.66%)
  • CAC 40

    -124.15 (-1.74%)

The US National Institute of Standards and Technology (NIST) has evaluated the use of Genomic Vision applications for genetic variant characterization

Genomic Vision
Genomic Vision


The US National Institute of Standards and Technology (NIST) has evaluated the use of Genomic Vision applications for genetic variant characterization

  • Genomic Vision’s technology demonstrated high accuracy for quantitative analysis of genomic events

  • This paves the way to establish standardized methods for cell characterization

Bagneux (France) – Genomic Vision (FR0011799907 – GV, the “Company”), a Euronext-listed biotechnology company that develops products and services for the highly accurate characterization of DNA sequences, is pleased to announce the successful evaluation of its DNA combing technology by the US National Institute of Standards and Technology (‘NIST’). The evaluation has confirmed the high accuracy of the technology for quantitative analysis of genomic events at or greater than 10 kilobases.

The NIST Genome Editing Consortium (‘Consortium’) is a public-private partnership consortium hosted by NIST to collaboratively address precompetitive genome editing measurements and standards (reference standards, reference methods, and reference data) needed to increase confidence in evaluating genome editing and utilizing these technologies in research and commercial products.

Within this Consortium, Genomic Vision’s Quality Control Assay (‘QCA’) was employed to identify, characterize, and quantify mid to large-size genomic variants occurring in a specific human population. The results were compiled by NIST and compared to other datasets obtained within the Consortium. NIST determined that Genomic Vision’s technology produced high quality results. The global results issued from the Consortium will be disclosed by NIST in spring 2023.

Genomic Vision’s technology allows for highly sensitive and digitally quantifiable analysis of structural and functional genome modifications and provides a quality control tool for the safety and optimization of engineered cells. The data output enables an unbiased assessment of genetic events through direct visualization of modifications on single DNA molecules.

Aaron Bensimon, Chief Executive Officer of Genomic Vision, commented: “We are pleased that our methodology for the characterization of naturally occurring mutations has received further validation, going through NIST’s rigorous interlaboratory study process blinded to the details about the genomic variants to be detected and performing to high standards. We believe our technology can become a gold standard for structural and functional genome analysis, with potential applications for quality control of cell and gene therapy products and bioproduction.”

Samantha Maragh, Ph.D., Project Leader of the Genome Editing program at NIST, commented: We are pleased to be working with Genomic Vision, a member of the NIST Genome Editing Consortium, and welcome their innovative QCA method of genome characterization to help advance the genome editing field. For this NIST Genome Editing Consortium Interlab Study, organizations were given a set of blinded qualified samples provided by NIST to assess their technologies. Genomic Vision’s technology demonstrated high accuracy for quantitative analysis of genomic events around 10 kilobases and greater.”

The Consortium numbers more than 40 academic and industrial members and Genomic Vision has been part of the NIST Consortium since 2019.

About Genomic Vision

GENOMIC VISION is a biotechnology company developing products and services dedicated to the structural and functional analysis of genome modifications as well as to the quality and safety control of these modifications, in particular in genome editing technologies and biomanufacturing processes. Genomic Vision proprietary products and services, based on DNA combing technology and artificial intelligence, provide robust quantitative measurements needed for high confidence characterization of DNA alteration in the genome. These products and services are also used for monitoring DNA replication in cells to improve anti-cancerous drugs development. Genomic Vision, based near Paris in Bagneux, is a public company listed in compartment C of Euronext’s regulated market in Paris (Euronext: GV – ISIN: FR0011799907).

For further information, please visit

About the National Institute of Standards and Technology (NIST)

The National Institute of Standards and Technology (NIST) was founded in 1901 and is now part of the U.S. Department of Commerce. NIST is one of the nation’s oldest physical science laboratories, and addresses measurement research needs in multiple fields including chemistry, IT, engineering and biology. The NIST Genome Editing Consortium addresses the measurements and standards needed to increase confidence of utilizing genome editing technologies in research and commercial products (

Genomic Vision
Aaron Bensimon
Phone: +33 1 49 08 07 51

Consilium Strategic Communications

International Investor Relations

& Strategic Communications

Tel: +44 (0) 20 3709 5700

Ulysse Communication

Media Relations

Bruno Arabian

Tél. : +33 1 42 68 29 70

Investor relations 
Phone: +33 1 44 71 94 94



        Member of the CAC® Mid & Small and CAC® All-Tradable indices


This press release contains implicitly or explicitly certain forward-looking statements concerning Genomic Vision and its business. Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the “Risk Factors” section of the universal registration document filed with the AMF on April 14, 2022 under reference number R.22-0293, as updated by the amendment filed with the AMF on May 20, 2022, under number D.22-0293-A01, available on the web site of Genomic Vision ( and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.

This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for Genomic Vision shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.